Phase III trial for once-monthly aripiprazole halted early on positive results
This article was originally published in Scrip
The independent data monitoring committee for a US Phase III trial with a new once-monthly formulation of Otsuka Pharmaceutical's antipsychotic, Abilify (aripiprazole), has recommended that the study be terminated early, following a positive interim analysis.
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.
Tislelizumab meets overall survival endpoint in later-line NSCLC at planned interim analysis, but faces exploding competition in the Chinese immuno-oncology sector.